E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
The FDA approval brings TUKYSA into the frontline maintenance setting, offering patients with HER2-positive metastatic breast cancer a chemotherapy-free option following initial treatment that may help delay disease progression.
imphoenix82
The US Food and Drug Administration (FDA) has approved Pfizer’s IBRANCE (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy as a maintenance treatment for adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer following induction treatment. IBRANCE is an oral inhibitor of […]
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
